Olivier Dirat
Research Subjects
Olivier Dirat has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Yves Langlois
Laboratoire de Synthèse des Substances Naturelles, associé au CNRS, ICMO, Bâtiment 410, Université de Paris-Sud, 91405 Orsay, France
4 shared publicationsA. Brian Jones
Merck co
3 shared publications- Andrew Teasdale
Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom
3 shared publications - Barry M. Trost
Department of Chemistry, Stanford University, Stanford, California 94305-5580, United States
3 shared publications Cyrille Kouklovsky
Laboratoire de Synthèse des Substances Naturelles, ICMO, Université Paris-Sud, F-91405 Orsay, France
3 shared publications- Ian W. Ashworth
Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (6) , 104296
Something in the air–Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment
- 24 April 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (6) , 104296
Open AccessSomething in the air–Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment
- Open Access
- 23 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1538-1553
Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines
- 23 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1538-1553
Open AccessDrug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines
- 21 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1152-1167
Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control
- 21 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1152-1167
Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control
- Top Cited Papers
- 16 January 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (3) , 331-344
Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles
Lipid nanoparticles (LNPs) for nucleic acid delivery often use novel lipids as functional excipients to modulate the biodistribution, pharmacokinetics, pharmacodynamics and efficacy of the nucleic acid. Novel excipients used in pharmaceutical products are subject to heightened regulatory scrutiny and often require data packages comparable to an active pharmaceutical ingredient. Although these regulatory requirements may help to ensure patient safety they also create economic and procedural barriers that can disincentivize innovation and delay clinical investigation. Despite the unique structural and functional role of lipid excipients in LNPs, there is limited specific global regulatory guidance, which adds uncertainty and risk to the development of LNPs. In this Perspective we provide an industry view on the chemistry, manufacturing and controls challenges that pharmaceutical companies face in the use of novel lipid excipients at each stage of development, and propose consensus recommendations on how to streamline and clarify development and regulatory expectations.
- 16 January 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (3) , 331-344
Top Cited PapersChemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles
Lipid nanoparticles (LNPs) for nucleic acid delivery often use novel lipids as functional excipients to modulate the biodistribution, pharmacokinetics, pharmacodynamics and efficacy of the nucleic acid. Novel excipients used in pharmaceutical products are subject to heightened regulatory scrutiny and often require data packages comparable to an active pharmaceutical ingredient. Although these regulatory requirements may help to ensure patient safety they also create economic and procedural barriers that can disincentivize innovation and delay clinical investigation. Despite the unique structural and functional role of lipid excipients in LNPs, there is limited specific global regulatory guidance, which adds uncertainty and risk to the development of LNPs. In this Perspective we provide an industry view on the chemistry, manufacturing and controls challenges that pharmaceutical companies face in the use of novel lipid excipients at each stage of development, and propose consensus recommendations on how to streamline and clarify development and regulatory expectations.
- 9 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4190-4193
Regulatory Highlights
- 9 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4190-4193
Regulatory Highlights
- 29 July 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (8) , 1382-1393
A Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity
Understanding the potential carcinogenic potency of nitrosamines is necessary to setting acceptable intake limits. Nitrosamines and the components that can form them are commonly present in food, water, cosmetics, and tobacco. The recent observation of nitrosamines in pharmaceuticals highlighted the need for effective methods to determine acceptable intake limits. Herein, we describe two computational models that utilize properties based upon quantum mechanical calculations in conjunction with mechanistic insights and established data to determine the carcinogenic potency of a variety of common nitrosamines. These models can be applied to experimentally untested nitrosamines to aid in the establishment of acceptable intake limits.
- 29 July 2024
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 37 (8) , 1382-1393
A Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity
Understanding the potential carcinogenic potency of nitrosamines is necessary to setting acceptable intake limits. Nitrosamines and the components that can form them are commonly present in food, water, cosmetics, and tobacco. The recent observation of nitrosamines in pharmaceuticals highlighted the need for effective methods to determine acceptable intake limits. Herein, we describe two computational models that utilize properties based upon quantum mechanical calculations in conjunction with mechanistic insights and established data to determine the carcinogenic potency of a variety of common nitrosamines. These models can be applied to experimentally untested nitrosamines to aid in the establishment of acceptable intake limits.
- 23 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3295-3306
Leveraging ICH M7 Control Options 3 and 4: Discussion and Clarification Using Industrial Case Studies
- 23 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3295-3306
Leveraging ICH M7 Control Options 3 and 4: Discussion and Clarification Using Industrial Case Studies
- Open Access
- 12 June 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2614-2622
Nitrite in Pharmaceutical Manufacturing Water: Development of an Ultra-Sensitive Analytical Method, Typical Data, and Discussion of Potential Nitrosamine Formation in Drug Substance and Drug Product from Water
- 12 June 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2614-2622
Open AccessNitrite in Pharmaceutical Manufacturing Water: Development of an Ultra-Sensitive Analytical Method, Typical Data, and Discussion of Potential Nitrosamine Formation in Drug Substance and Drug Product from Water
- 28 June 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (7) , 1269-1275
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
- 28 June 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (7) , 1269-1275
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates